In pancreatic ductal adenocarcinoma (PDAC), nearly 90% of all patients harbor a KRAS mutation (2) and these mutations are implicated in the initiation, maintenance, and progression of pancreatic tumors (3). Here, KRAS is linked to pancreatic ductal adenocarcinoma.